Sonova highlights analyst views and strategy, shares in SMI healthcare sector

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:12.

Sonova Holding AG (CH0012549785) sits among the larger healthcare names on the SIX Swiss Exchange, with the stock included in the Swiss Market Index alongside peers such as Roche and Novartis. Analyst commentary and consensus data set the tone for how investors are currently valuing the hearing-care specialist.

What recent analysts say

UBS has recently reiterated a Buy rating on Sonova, with a price target in the low-300 Swiss franc range according to consensus aggregators that compile major investment bank views. MarketScreener data shows that most covering analysts maintain positive to neutral stances on the shares, reflecting expectations of steady earnings growth over the coming years.

The distribution of ratings includes Buy, Outperform and Hold recommendations from houses such as UBS, Credit Suisse and JPMorgan, mapped into an average target price that typically sits above the current market level by a moderate margin. According to one consensus snapshot, more than two-thirds of analysts rate the Sonova stock as a Buy or equivalent, while only a small minority see it as a Sell.

How consensus frames Sonova

Consensus estimates compiled by MarketScreener point to mid-single-digit to high-single-digit revenue growth for Sonova over the next two financial years, paired with margin expansion driven by operational efficiency and higher-value products. Earnings per share projections typically imply a forward price-earnings ratio in the low-20s, situating Sonova within a premium but not extreme valuation bracket for medtech names.

Some analyst notes highlight Sonova's exposure to structural drivers such as aging populations and rising awareness of hearing health, while also flagging currency fluctuations and competition from rivals like Demant and GN Store Nord as factors that may influence quarterly volatility. The consensus view tends to see Sonova as a solid compounder within the European medical technology sector rather than a high-beta momentum stock.

The product behind the stock

Sonova generates most of its revenue from hearing solutions such as Phonak-branded hearing aids and cochlear implants, complemented by wireless communication products and audiological services. These devices are designed to address mild to profound hearing loss across age groups, with a strong presence in Europe and North America.

Where the stock trades today

Sonova shares (CH0012549785) trade on the SIX Swiss Exchange in Zurich, with the last verified closing price at around the mid-200s Swiss franc level and a market capitalization comfortably in the multi-billion-franc range as of the most recent trading day.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any financial instrument. All data were obtained from sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.